PHARMACEUTICAL COMPOSITION OF NOVEL CORONAVIRUS ANTIBODY AND USE THEREOF

摘要

Disclosed are a pharmaceutical composition of a humanized monoclonal antibody against novel coronavirus (2019-nCoV) and the use thereof in medicine. The pharmaceutical composition contains an antibody that specifically binds to 2019-nCoV RBD, or an antigen-binding fragment thereof, a buffer, and may also contain at least one stabilizer, and optionally a surfactant.